North America Sulfonylureas Market Projected to Grow, Hitting USD 3.35 Billion Valuation by 2028 with Notable CAGR of 1.90%
January 30, 2024 20:00 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "North America Sulfonylureas Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
China Diabetes Care Drugs Market to Reach USD 13.73 Billion by 2028, Propelled by Rising Prevalence and Advanced Treatment Options
January 30, 2024 19:57 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "China Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
RYZODEG Drug & Market Forecast Report 2023-2032: Reveals Comprehensive Insights for Type 1 Diabetes Mellitus Treatment - Mechanism of Action, Clinical Assessments, Market Dynamics, Emerging Competitors
January 30, 2024 06:58 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "RYZODEG Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Offering an in-depth analysis of the...
Cell Therapies for Type 1 Diabetes: 2023-2030 Industry Outlook Featuring Analysis of Leading Players Novo Nordisk, Sanofi, Vertex Pharmaceuticals, Sernova, and Throne Biotechnologies
January 30, 2024 04:49 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapies for Type 1 Diabetes (2023 Edition): Global and Country Analysis By Epidemiology, Pipeline and Target Market Assessment" report has been...
PRV-031 (teplizumab) Drug Insight and Market Forecast to 2032: Highlights Opportunities Across Key Regions
January 29, 2024 12:21 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "PRV-031 Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report reveals extensive insights...
Diabetes Care Advances: LEVEMIR Drug Insight and 2032 Market Forecast Revealed
January 24, 2024 10:50 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "LEVEMIR Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The healthcare industry has taken a...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
January 09, 2024 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+...
Global Glucagon-like Peptide 1 (GLP-1) Market Soars to $18.75 Billion by 2023, Fueled by Increasing Healthcare Expenditure and Aging Population
November 10, 2023 08:48 ET
|
Research and Markets
Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Glucagon-like Peptide 1 (GLP-1) Market (by Product, Route of Administration, & Region): Insights and Forecast with Potential Impact of...
Diabetes Drugs Market Size to Surpass USD 134.08 Billion by 2030, exhibiting a CAGR of 7.8%
October 25, 2023 07:15 ET
|
Fortune Business Insights
Pune, India, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The global diabetes drugs market size was valued at USD 66.15 billion in 2022, and it is expected to expand from USD 79.25 billion in 2023 to USD...
Global Diabetes Epidemic: Unprecedented Economic Burden of $966 Billion in 2021 Underscores Urgency for Innovative Therapeutics and Diagnostics
September 18, 2023 07:38 ET
|
Research and Markets
Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The "Global Markets for Diabetes Therapeutics and Diagnostics" report has been added to ResearchAndMarkets.com's offering. The latest market analysis...